The DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index.
Inhibition of the Differentiation of Dendritic Cells From CD34+ Progenitors by Tumor Cells: Role of Interleukin-6 and Macrophage Colony-Stimulating Factor
Abstract
The escape of malignant cells from the immune response against the tumor may result from a defective differentiation or function of professional antigen-presenting cells (APC), ie, dendritic cells (DC). To test this hypothesis, the effect of human renal cell carcinoma cell lines (RCC) on the development of DC from CD34(+) progenitors was investigated in vitro. RCC cell lines were found to release soluble factors that inhibit the differentiation of CD34(+) cells into DC and trigger their commitment towards monocytic cells (CD14(+)CD64(+)CD1a-CD86(-)CD80(-)HLA-D Rlow) with a potent phagocytic capacity but lacking APC function. RCC CM were found to act on the two distinct subpopulations emerging in the culture at day 6 ([CD14(+)CD1a-] and [CD14(-)CD1a+]) by inhibiting the differentiation into DC of [CD14(+)CD1a-] precursors and blocking the acquisition of APC function of the [CD14(-)CD1a+] derived DC. Interleukin-6 (IL-6) and macrophage colony-stimulating factor (M-CSF) were found to be responsible for this phenomenon: antibodies against IL-6 and M-CSF abrogated the inhibitory effects of RCC CM; and recombinant IL-6 and/or M-CSF inhibited the differentiation of DC similarly to RCC CM. The inhibition of DC differentiation by RCC CM was preceeded by an induction of M-CSF receptor (M-CSFR; CD115) and a loss of granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR; CD116) expression at the surface of CD34(+) cells, two phenomenon reversed by anti-IL-6/IL-6R and anti-M-C…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CSF-2 in isolation also promotes their differentiation into a dendritic cell lineage, which maintains a phagocytic phenotype (CD68 immunopositive) [17, 30].”
From Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy (2020) · cites this paper as [30]
Citations
Cites
The Dendritic Cell System and its Role in Immunogenicity
Steinman, R. M. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.001415 · Cited by 4,659
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804
GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells
Caux, C., Dezutter‐Dambuyant, C., Schmitt, D., & Banchereau, J. (1992) · Nature · doi:10.1038/360258a0 · Cited by 1,551
Self-citationSchwartz, R. H. (1992) · Cell · doi:10.1016/s0092-8674(05)80055-8 · Cited by 1,293
Induction of tolerance by IL-10-treated dendritic cells
Steinbrink, K., Wölfl, M., Jonuleit, H., Knop, J., & Enk, A. H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.10.4772 · Cited by 1,245
Caux, C., Vanbervliet, B., Massacrier, C., Dezutter‐Dambuyant, C., de Saint-Vis, B., Jacquet, C., Yoneda, K., Imamura, S., Schmitt, D., & Banchereau, J. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.2.695 · Cited by 920
Self-citationZitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., & Storkus, W. J. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.1.87 · Cited by 824
Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily.
Zhou, L., & Tedder, T. F. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.8.3821 · Cited by 751
Kawasaki, E. S., Ladner, M. B., Wang, A. M., Arsdell, J. V., Warren, M. K., Coyne, M. Y., Schweickart, V. L., Lee, M.-T., Wilson, K. J., Boosman, A., et al. (1985) · Science · doi:10.1126/science.2996129 · Cited by 523
Research works printed but not linked: 1
- Négrier, 1996, The FNCLCC CRECY trial: Interleukin 2 (IL2) + interferon (IFN)-α is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC)., Proc Am Soc Clin Oncol, 15, 248
Cited by
Sorted by citations
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1256 · Cited by 3,413
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature reviews. Immunology · doi:10.1038/nri1703 · Cited by 3,175
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Metadata
- Authors
- Menetrier-Caux, C., Montmain, G., Dieu, M. C., Bain, C., Favrot, M. C., Caux, C., & Blay, J. Y.
- Affiliations
- From Unité Cytokine et Cancer, Unité INSERM 453, Centre Léon Bérard, Lyon, France; and Schering Plough, Dardilly, France.
- Inserm (FR)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1998-12-15
- Volume
- 92
- Issue
- 12
- Pages
- 4778-4791
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W193748226
- Cited by
- 590
- References
- 48
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 10 · 2023: 10 · 2022: 8 · 2021: 9 · 2020: 20 · 2019: 16 · 2018: 13 · 2017: 9 · 2016: 25 · 2015: 26 · 2014: 19 · 2013: 30 · 2012: 25
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- dendritic cell differentiation, CD34+ progenitors, renal cell carcinoma, tumor immune evasion, interleukin-6, macrophage colony-stimulating factor, M-CSF receptor, GM-CSF receptor, antigen-presenting cells, monocyte differentiation, CD1a, CD14, soluble factors
- MeSH terms
- Antibodies, Carcinoma, Renal Cell, Cell Differentiation, Cell Division, Dendritic Cells, Dose-Response Relationship, Drug, Gene Expression Regulation, Humans, Lymphokines, Tumor Cells, Cultured, Interleukin-6, Immunophenotyping, Macrophage Colony-Stimulating Factor, Receptor, Macrophage Colony-Stimulating Factor, Receptors, Granulocyte-Macrophage Colony-Stimulating Factor, Endothelial Growth Factors, Culture Media, Conditioned, Antigens, CD34, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Cell Size
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
